Abstract: Pain associated with primary and secondary dysmenorrhea is relieved in a human suffering there from by administering to the human a pain relieving amount of a synergistically acting sub-therapeutic combination of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, magnesium, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, tramadol or its analog such as recemic tramadol or an analogously acting molecular entity or pharmaceutically acceptable salt thereof, and an anticonvulsant and/or a tricyclic anti-depressant or pharmaceutically acceptable salt thereof, and optionally in sustained release dosage form.

Abstract: The present invention relates to the formulations of ester derivatives of capsaicin and ester derivatives of myristoleic acid. These derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis. These derivatives have a higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound, and hence are better able to be incorporated into certain pharmaceutical formulations, including cream and ointment pharmaceutical formulations. The pharmaceutical compositions are useful for pain management in mammals in vivo and have been contemplated to be used in the treatment of various pains in humans.

Abstract: The present invention relates to formulations comprising amyris alcohol or an ester of amyris alcohol or combinations thereof to treat acne in humans. These formulations can further comprise a phytoestrogen such as glabridin and miroestrol, an antioxidant such as tetrahydrocurcumin and naturally occurring peroxides such as artemisinin and dihydroartemisinin and combinations thereof for improved effectiveness in treating acne.

Abstract: The invention provides orally administered antitussive pharmaceutical compositions comprising dextromethorphan, wherein the compositions are free of bromide, sodium and polistirex.

Abstract: The present invention relates to the formulations of ester derivatives of capsaicin and ester derivatives of myristoleic acid. These derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis. These derivatives have a higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound, and hence are better able to be incorporated into certain pharmaceutical formulations, including cream and ointment pharmaceutical formulations. The pharmaceutical compositions of the present invention contain a compound of following formula (Ia): R—CO—CAP??(Ia) wherein CAP refers to collectively the capsaicins represented in FIG. 1 and a compound of formula (Ib): MCO—O—R??(Ib) wherein MCO refers to myristoleic acid.

Abstract: The present invention relates to the formulations of ester derivatives of capsaicin and ester derivatives of myristoleic acid. These derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis. These derivatives have a higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound, and hence are better able to be incorporated into certain pharmaceutical formulations, including cream and ointment pharmaceutical formulations. The pharmaceutical compositions of the present invention contain a compound of following formula (Ia): R—CO-CAP??(Ia) wherein CAP refers to collectively the capsaicins represented in FIG. 1 and a compound of formula (Ib): MCO-O—R??(Ib) wherein MCO refers to myristoleic acid.

Abstract: The present invention relates to the formulations of ester derivatives of sandalwood oil and santalol. These derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis. These derivatives have a higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound, and hence are better able to be incorporated into certain pharmaceutical formulations, including cream and ointment pharmaceutical formulations. The compounds of the present invention are set forth by the following formula: The present invention generally pertains to a compound of formula (I): R—CO—SWO??(I) wherein SWO refers to collectively the alcohols, including santalol, present in the sandalwood oil; wherein R is selected from alkyl groups of up to about 22 carbon atoms and aryl groups of up to about 22 carbon atoms and alkylene group of up to about 22 carbon atoms and an arylene group of up to about 22 carbon atoms.

Abstract: Chronic pain is alleviated in a mammal suffering there from by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, in combination with a ?-opiate analgesic such as tramadol or an analogously acting molecular entity, and a capsaicin or an ester of capsaicin, and optionally in sustained release dosage form.

Abstract: The present invention relates to the formulations of ester derivatives of capsaicin and ester derivatives of myristoleic acid. These derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis. These derivatives have a higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound, and hence are better able to be incorporated into certain pharmaceutical formulations, including cream and ointment pharmaceutical formulations. The pharmaceutical compositions of the present invention contain a compound of following formula (Ia): R—CO-CAP ??(Ia) wherein CAP refers to collectively the capsaicins represented in FIG. 1 and a compound of formula (Ib): MCO-O—R ??(Ib) wherein MCO refers to myristoleic acid.